FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata | Region
NEW YORK--(BUSINESS WIRE)--Jun 23, 2023--
Source: eagletribune.com
Page 9 - Clinical Trial Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Trial Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Trial Program Today - Breaking & Trending Today
FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata - Pfizer (NYSE:PFE)
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12 Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved
Source: benzinga.com
FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Source: marketscreener.com
Bristol Myers Squibb Receives European Commission Approval of Sotyktu, a Once-Daily Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Sotyktu , a first-in-class, selective tyrosine kinase 2 inhibitor, for the treatment of adults with... | March 29, 2023
Source: marketscreener.com
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical... | March 28, 2023
Source: marketscreener.com